Pralatrexate
A dihydrofolate reductase inhibitor
General information
Pralatrexate is a folate analogue, which inhibits dihydrofolate reductase. It has antineoplastic and immunosuppressive properties (NCIt).
Pralatrexate on DrugBank
Pralatrexate on PubChem
Pralatrexate on Wikipedia
Marketed as
FOLOTYN
C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro
RdRpol AI Biophysical assay Small molecule In vitro In silico |
in silico (AI); in vitro biophysical assay; Vero cells; SARS-CoV-2 strain BetaCoV/Shenzhen/SZTH-003/2020 (GISAID No. EPI_ISL_406594) | 4.38 | Inhibited SARS-CoV-2 replication with EC50 of 0.008 μM and SI of 20.878 in Vero cells. The drug acted on the post-entry stages of infection. |
Dec/31/2020 |
|
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
Small molecule In vitro |
Vero cells; Calu-3 cells; Madin-Darby canine kidney cells; SARS-CoV-2 strain BetaCoV/korea/KCDC03/2020 | 3.47 | The drug reduced viral replication in a dose-dependent manner (IC50s of 0.02–0.054 μM). It displayed significant efficacy even when added 13 hours post infection in Calu-3 cells. It was cytotoxic only at high concentrations (SI values of >1,851). |
Mar/17/2021 |
